News

N30 Pharma Raises $30 Million to Advance Investigational CF Drug

Clinical-stage biopharmaceutical company, N30 Pharmaceuticals, recently announced that it raised $30 million in a mezzanine round of financing, which will be used to accelerate the development the company’s investigational therapy for the treatment of cystic fibrosis (CF). The novel drug is called N91115 and N30 Pharma has successfully completed its phase…

New CF Therapies Possible Based on Research Into Protein Folding

In a recent study entitled “Modulation of the Maladaptive Stress Response to Manage Diseases of Protein Folding,” a team of researchers showed that in protein misfolding diseases, such as cystic fibrosis and Alzheimer’s disease, the cells’ response to misfolding proteins can actually exacerbate the disease phenotype. The study was published in the …

Can Cystic Fibrosis Treatment Improve Thanks To a Ferret?

A major breakthrough in the understanding of respiratory diseases entitled “The draft genome sequence of the ferret (Mustela putorius furo) facilitates study of human respiratory disease” was published on Nature Biotechnology by Dr. Xinxia Peng at the University of Washington in Seattle and Federica Di…

Arcturus Presents mRNA Delivery Data Applicable to CF Treatment

Arcturus Therapeutics, Inc. recently presented encouraging non-human primate studies concerning its preclinical messenger RNA therapies for the potential treatment of genetic diseases such as cystic fibrosis at the 2nd International mRNA Health Conference held November 11-12 in Cambridge, Massachusetts. Arcturus’ presentation, “Potent Delivery of LUNAR™ Nanoparticles Containing Synthetic mRNA for…